Alaunos Therapeutics (TCRT) Accumulated Expenses (2009 - 2026)

Alaunos Therapeutics has reported Accumulated Expenses for 18 years, with the latest figure at $195000.0 in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses fell 15.58% year-over-year to $195000.0; the trailing twelve-month figure through Mar 2026 stood at $195000.0 (down 15.58% YoY), and the FY2025 full-year result was $200000.0, up 13.64% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $195000.0, down from $200000.0 in the prior quarter.
• The five-year high for Accumulated Expenses was $7.7 million in Q3 2022, with the low at $78000.0 in Q3 2025.
• Historically, Accumulated Expenses has averaged $2.0 million across 5 years, with a median of $568000.0 in 2023.
• Annual changes were most pronounced in 2022 — Accumulated Expenses soared 881.83% — and 2024, when it slumped 88.02%.
• Alaunos Therapeutics' Accumulated Expenses stood at $1.2 million in 2022, then tumbled by 51.03% to $568000.0 in 2023, then sank by 69.01% to $176000.0 in 2024, then advanced by 13.64% to $200000.0 in 2025, then retreated by 2.5% to $195000.0 in 2026.
• The last three Accumulated Expenses figures came in at $195000.0 (Q1 2026), $200000.0 (Q4 2025), and $78000.0 (Q3 2025), per Business Quant data.